메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025

SINGAPORE, Oct. 18, 2025 -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I trial (NCT06544720) in patients with recurrent or metastatic HPV-associated carcinomas. The poster will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on Saturday, 18 October 2025. This ongoing first-in-human trial evaluates the safety,
- 김갑성 기자
- 2025-10-18 13:00
One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions

GUANGZHOU, China, Oct. 18, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
- 김갑성 기자
- 2025-10-18 11:06
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

[ 메디채널 김갑성 기자 ] AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with heavily pretreated EGFR Wild-type NSCLC and other advanced solid tumors without CD44v9 pre-selection SHANGHAI, Oct. 17, 2025 -- Multitude Therapeutics, Inc., a clinical-stage company focused on the development of antibody-drug-conjugate (ADC) drugs, today announced initial data from its ongoing phase I/II
- 김갑성 기자
- 2025-10-17 22:00
NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension

NEW YORK, Oct. 17, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension Kristen Scholer delivers the pre-market update on October 17th Stocks are lower early Friday after regional bank reports created concerns over bad loans. Loose lending practices pushed traders into safe havens. Activity in the banking sector could infor
- 황정호 기자
- 2025-10-17 20:55
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

CHENGDU, China, Oct. 17, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have received one or more prior anti-HER2 therapy. The approval is based on a multi-center, randomized, open-label
- 김갑성 기자
- 2025-10-17 20:22
One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions

GUANGZHOU, China, Oct. 17, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
- 김갑성 기자
- 2025-10-17 18:39
One Heung Kong Leads the Way! New Global Benchmark for Healthy Living Announced

GUANGZHOU, China, Oct. 17, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
- 김갑성 기자
- 2025-10-17 18:35
HMI Medical Signs MOA With Ibraco Berhad To Acquire Land For The Establishment Of Its Third Hospital In Malaysia

The new tertiary hospital will be located within the NorthBank Township in Kuching, Sarawak and is targeted to launch in 2029 SINGAPORE, Oct. 17, 2025 -- Health Mangement International Pte Ltd ("HMI Medical") has signed a Memorandum of Agreement ("MoA") with KLSE listed and Sarawak-based property and infrastructure developer, Ibraco Berhad, ("Ibraco") for the acquisition of land for the construction of its third hospital in Malaysia. Fully owned and operated by HMI Medical, Regency Hospital Kuching, a new private specialist hospital will be located
- 김갑성 기자
- 2025-10-17 16:49
Chula Launches Newborn Genome Sequencing Project for Early Detection and Prevention of Genetic Diseases

BANGKOK, Oct. 17, 2025 -- The Center of Excellence in Medical Genetics, Faculty of Medicine, Chulalongkorn University, has launched one of the world's first projects to perform long-read whole genome sequencing in newborns. The initiative screens for 113 genetic diseases, with the goal of early prevention and treatment, opening a new frontier in precision medicine and improving lifelong health outcomes. Genomic Medicine: A New Dimension in Health Care Modern medicine has entered a new era by decoding the genetic foundations of diseases. Genomic medicine can reveal who i
- 김갑성 기자
- 2025-10-17 16:00
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

[ 메디채널 김갑성 기자 ] New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide Intention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX) Name change to be effective following shareholder approval, which is expected at the Extraordinary General Meeting (EGM) on October 24, 2025 Pending acquisition of AM712 (also know
- 김갑성 기자
- 2025-10-17 15:21

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 19시 40분